Merck Sharp + Dohme Corp.

Merck Canada Inc.

Vijayasaradhi Sivalenka

John A McCauley

Peter D Williams

M Katharine Holloway

Christopher James Bungard

David Jonathan Bennett

Satyanarayana Tummanapalli

Michael P Dwyer

Bin Hu

Dong-Ming Shen

Sherman Tim Waddell

Oscar Miguel Moradei

Thomas J Greshock

Gregori J Morriello

Xin-Jie Chu

Kartik M Keertikar

Lehua Chang

Nicolas Zorn

Tao Ji

Vouy Linh Truong

Christian Beaulieu

Bin Zhong

Carmela Molinaro

Edward C Sherer

Catherine M Wiscount

Sheldon N Crane

H Marie Loughran

Stephanie Lessard

Daniel Mckay

Jessie J Manikowski

Jurgen Schultz

John A Mccauley

The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z, Z, V, V, V, R, R, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. 

HIV protease inhibitors

The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

Piperazine derivatives as HIV protease inhibitors

Growing community of inventors

Singapore, Singapore

Vijayasaradhi Sivalenka